![](/img/cover-not-exists.png)
Cell-bound complement activation products (CB-CAPs) have high sensitivity and specificity in pediatric-onset systemic lupus erythematosus and correlate with disease activity
Hui-Yuen, J S, Gartshteyn, Y, Ma, M, O’Malley, T, Conklin, J, Eichenfield, A H, Imundo, L F, Dervieux, T, Askanase, A DLanguage:
english
Journal:
Lupus
DOI:
10.1177/0961203318809181
Date:
October, 2018
File:
PDF, 148 KB
english, 2018